Dyne Therapeutics (NASDAQ:DYN) Reaches New 1-Year Low - What's Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s stock price reached a new 52-week low during trading on Friday . The company traded as low as $14.48 and last traded at $14.77, with a volume of 2292168 shares trading hands. The stock had previously closed at $15.54.

Analysts Set New Price Targets

DYN has been the topic of a number of research reports. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an "outperform" rating and a $46.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, January 10th. HC Wainwright reiterated a "buy" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday. Finally, Piper Sandler reissued an "overweight" rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $49.91.

Dyne Therapeutics Stock Performance

The company's 50 day simple moving average is $25.92 and its 200 day simple moving average is $33.47. The stock has a market cap of $1.44 billion, a PE ratio of -3.97 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,334 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the firm's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares of the company's stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,071 shares of company stock valued at $606,476 over the last three months. Company insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of the business. FMR LLC grew its position in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company's stock valued at $324,239,000 after buying an additional 3,707,734 shares during the period. RTW Investments LP lifted its stake in Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock worth $244,926,000 after purchasing an additional 431,503 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Dyne Therapeutics by 47.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock valued at $244,755,000 after buying an additional 2,189,339 shares in the last quarter. RA Capital Management L.P. grew its holdings in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company's stock worth $130,816,000 after buying an additional 440,890 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.